Head-to-head comparison
| Property | AOD-9604 | Tesamorelin |
|---|---|---|
| Category | Weight Loss | Muscle & Growth |
| Legal Status | Reclassification Pending | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~1-2 hours | ~26-38 minutes |
| Mol. Weight | 1,815.08 Da | 5,135.89 Da |
| Side Effects | Injection site redness, Headache, Mild nausea | Injection site reactions (pain, redness), Joint pain, Nausea |
Key differences
- Evidence quality: Tesamorelin has published Phase III clinical trials and FDA approval; AOD-9604 failed its Phase IIb obesity trial and is not FDA-approved for any therapeutic indication.
- Mechanism: Tesamorelin is a GHRH analog that stimulates the pituitary to release growth hormone; AOD-9604 is a modified fragment of hGH (residues 177-191) proposed to stimulate lipolysis without full GH effects.
- FDA status: Tesamorelin is FDA-approved as Egrifta SV for HIV-associated lipodystrophy; AOD-9604 has GRAS status as a food ingredient only, not as a therapeutic.
- GH/IGF-1 effects: Tesamorelin significantly raises GH and IGF-1 levels; AOD-9604 was specifically designed not to affect GH or IGF-1.
- Fat reduction evidence: Tesamorelin reduced trunk fat by approximately 18% in clinical trials; AOD-9604 did not demonstrate statistically significant weight loss over placebo.
- Prescription status: Tesamorelin is a prescription medication; AOD-9604 is available as a research compound from unregulated suppliers.
- Dosing: Tesamorelin is dosed at 2 mg daily subcutaneously; AOD-9604 is typically dosed at 250–300 mcg daily subcutaneously in off-label protocols.
The verdict
Tesamorelin is the clearly stronger option with FDA approval, published clinical efficacy data, and an established safety profile. AOD-9604 failed to demonstrate weight loss efficacy in its clinical trial and has no therapeutic FDA approval. The only advantage AOD-9604 offers is that it does not raise GH/IGF-1 levels, which could theoretically matter for individuals who cannot tolerate GH elevation. For evidence-based fat reduction, tesamorelin is the supported choice.
Frequently asked questions
No. Tesamorelin has demonstrated approximately 18% trunk fat reduction in Phase III trials and has FDA approval. AOD-9604 failed to show statistically significant weight loss over placebo in its Phase IIb trial. The evidence gap is substantial.
No, AOD-9604 was specifically designed to retain the fat-burning fragment of GH without raising GH or IGF-1 levels. Tesamorelin, as a GHRH analog, significantly increases both GH and IGF-1. This distinction matters for individuals concerned about IGF-1 elevation.
AOD-9604 remains popular in biohacking communities due to its theoretical mechanism, its GRAS status (often misinterpreted as efficacy approval), and its availability from peptide vendors. Community anecdotal reports persist despite the absence of clinical trial support.
Yes, tesamorelin is FDA-approved and available by prescription as Egrifta SV. Its labeled indication is HIV-associated lipodystrophy, so off-label prescribing for general fat loss depends on physician discretion and insurance coverage.
They operate through different GH-axis mechanisms (GHRH stimulation vs GH fragment). No clinical data exists on this combination. Given AOD-9604's lack of demonstrated efficacy, the rationale for adding it to tesamorelin therapy is unclear.